Endocrine Abstracts

JOINT2109

Objective: To compare six-month follow-up data of children who started somatrogon (once-weekly), switched from somatropin to somatrogon and started somatropin (once-daily) due to growth hormone deficiency (GHD).

Materials-Methods: Children who met the study criteria organised as three study groups [somatrogon group, switch group (from somatropin to somatrogon) and somatropin group] and followed for six months. The findings were presented as percentages (number) and mean values with standard deviation (SD). While the data of the somatrogon and the switch group were collected prospectively, the data of the somatropin group were collected retrospectively. Bioimpedance analysis and the quality of life scales (“Pediatric Quality of Life Inventory”, “Child Behavior Checklist” and “Multidimensional Perceived Social Support Scale”) performed at the initiation, at the 3rd and 6th months of treatment in somatrogon and switch groups.

Results: Forty-eight patients (58. 4% male) were included. Somatrogon group (n = 17), switch group (n = 14) and somatropin group (n = 17) had mean ages of 11. 5±2. 9, 9. 3±3. 6, 10. 7±3. 1 years, mean height SDS of -2. 9±0. 8, -1. 7±0. 6, -2. 7±0. 5 and mean bone age SDS of -2. 3±1. 1, -2. 1±0. 7, -2. 5±0. 9, respectively. Most patient’s pituitary magnetic resonance imagination (77%, n = 37) was normal and empty sella was the most common abnormality (8. 3%, n = 4). Somatropin’s mean initial dosage was 0. 030±0. 003 mg/kg/day, whereas somatrogon’s was 0. 66 mg/kg/week. The mean change in height SDS at 6 months was 0. 3±0. 2, 0. 4±0. 2, 0. 5±0. 3, respectively (P = 0. 203). The mean height velocity (HV) were 11±2. 5, 10. 2±2. 2, 11. 3±2. 6 cm/year (P = 0. 533). and the mean HV SDS were 2. 6±1. 7, 2. 6±1. 7, 2. 9±2. 2, respectively at six months (P = 0. 860). No dose reduction or treatment interruption was required due to side effects. The mean change in IGF-1SDS at 6 months were 2. 1±1. 4, 1. 4±0. 6, 1. 2±1. 0 respectively (P = 0. 099). The mean change in body fat percentage of somatrogon and switch group at 6 months were -3. 5±13. 4, 5. 4±7. 4 respectively (P = 0. 115) Neither the group that started somatrogon nor the somatrogon transition group had significant change in the quality of life score at six month compared to the beginning of treatment (p>0. 05). While there was a significant difference between the groups in terms of baseline externalization symptoms (P = 0. 020), no significant difference was found at the 6th month (P = 0. 134).

Conclusion: The efficacy, tolerability and quality of life of once-weekly somatrogon were likely to those of once-daily somatropin for GHD.

Note: The study is still ongoing and a preliminary analysis has been conducted based on 41 patients with completed 6-month data. The full dataset is expected to be completed by the time of the conference.